Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus CLARITIN D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus CLARITIN D.
CHILDREN'S ZYRTEC ALLERGY vs CLARITIN-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral H1 histamine receptors, inhibiting histamine-mediated allergic and inflammatory responses.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
5 mg (1 tablet or 5 mL oral solution) once daily; dosing frequency may be increased to 10 mg once daily (2 tablets or 10 mL) for more severe symptoms.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
None Documented
None Documented
Terminal half-life 8.5–10.5 hours in children 2–5 years; 9–11 hours in children 6–12 years; 8–9 hours in adults. Clinically, supports once-daily dosing.
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Primarily renal (60% unchanged) via tubular secretion; 40% metabolized in liver to inactive metabolites excreted in urine; <1% fecal.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination